$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
帕博西林+来曲唑治疗转移性乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕利降低三阴性乳腺癌患者的死亡风险
2025-10-19 11:44:20
Check Details
哌柏西利联合来曲唑转移性乳腺癌的一线治疗方案
2025-10-19 11:44:20
Check Details
哌柏西利联合来曲唑治疗乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼获批治疗转移性胰腺癌患者
2025-10-19 11:44:20
Check Details
帕博西林治疗三阴乳腺癌效果如何?
2025-10-19 11:44:20
Check Details
来曲唑联合拉帕替尼治疗早期乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗HER2阴性的转移性乳腺癌
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗遗传性乳腺癌
2025-10-19 11:44:20
Check Details
帕博西尼联合来曲唑联治疗晚期乳腺癌
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗BRCA突变乳腺癌患者
2025-10-19 11:44:20
Check Details
帕博西林+氟维司群治疗乳腺癌
2025-10-19 11:44:20
Check Details
1
2
...
1660
1661
1662
1663
1664
1665
1666
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
4
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
5
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
6
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
7
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
8
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
9
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
10
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
11
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
12
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use